Despite the initial benefits of EGFR inhibitors in cancer patients harboring EGFR mutations, the rapid development of acquired resistance (AR) is a major obstacle in clinical practice and often leads to therapeutic failure and disease recurrence. Here, EGFR is linked to cancer.